British American Tobacco (BATS.L) — Company Research

Last Updated: 25 April 2026

British American Tobacco p.l.c. (LSE: BATS) is a FTSE 100 multinational based in London with brands sold in roughly 180 markets. FY2025 results released on 12 February 2026 hit the top end of management’s prior-year guidance: revenue £25,610m (−1.0% reported / +2.1% at constant currency), adjusted profit from operations £11,572m (+0.4% c.c.), adjusted diluted EPS 352.1p (+0.7% c.c.), full-year dividend 245.04p (+2.0%) and a £1.3bn 2026 share buyback. Smokeless products (Vuse vapour, glo heated tobacco, Velo modern oral, Zonnic NRT) are now 18.2% of group revenue (+70bps YoY) and category contribution swung to £427m (+77.1%) at an 11.8% margin. The 15 April 2026 AGM, the 21 April 2026 final passing of the UK Tobacco and Vapes Bill (generational sales ban from 1 January 2027), the appointment of Dragos Constantinescu as incoming CFO from 1 September 2026, and the May 2025 sell-down of a further ~2.5% of ITC Limited (now ~22.93% then ~20.3% post-deal) all sit on top of an industry under intense regulatory scrutiny. This report distils the FY25 numbers, segment splits, the smokeless transition, valuation, ITC stake history, US litigation context and last-48-hour activity entirely from BAT’s own RNS, results announcements and AGM materials — no analyst opinions, no price targets. For live charts and watchlists see our live charts, the economic calendar, and the community forum.

1. Company Snapshot

Name	British American Tobacco p.l.c.
Ticker	LSE: BATS (FTSE 100); NYSE ADR: BTI; ISIN GB0002875804
Sector	Tobacco & Nicotine — combustibles (Dunhill, Lucky Strike, Pall Mall, Camel, Newport, Kent, Rothmans) and smokeless / "New Categories" (Vuse vapour, glo heated tobacco, Velo modern oral, Zonnic NRT)
Headquarters	Globe House, 4 Temple Place, London WC2R 2PG, United Kingdom
Heritage	Founded 1902 as a joint venture between Imperial Tobacco (UK) and American Tobacco (US). Acquired Reynolds American (RAI) in July 2017 for ~$49bn, becoming #1 in the US tobacco market. ITC Limited (India) stake dates back to 1910.
CEO	Tadeu Marroco (Chief Executive since May 2023; previously Group Finance Director)
CFO	Javed Iqbal (Interim CFO); Dragos Constantinescu joins as permanent CFO and Executive Director on 1 September 2026 (currently CEO Asahi Europe & International; 16 prior years at BAT)
Chair	Luc Jobin (tenure extended by 2 years per Feb 2026 board update)
Employees	~46,000 globally
Smokeless consumers	34.1m at FY25 (+4.7m YoY); long-term target 50m by 2030
FY2025 revenue	£25,610m (−1.0% reported, +2.1% constant currency)
FY2025 adj. profit from operations	£11,572m (+0.4% c.c.); adj. operating margin 44.0%
FY2025 adjusted diluted EPS	352.1p (+0.7% c.c.)
FY2025 dividend	245.04p (+2.0%)
2026 buyback	£1.3bn programme
Adj. net debt / EBITDA	2.48x (FY25; target 2.0–2.5x by year-end 2026)
Share price (24 Apr 2026)	~4,143p (close 23 Apr; market closed Saturday 25 Apr)
Market cap (24 Apr 2026)	~£90bn
Website	bat.com

2. Bull Case vs Bear Case

Bull Case

• FY2025 hit the top end of guidance: revenue +2.1% c.c., adjusted profit from operations +0.4% c.c., adjusted diluted EPS +0.7% c.c.; CEO Tadeu Marroco reiterated the medium-term financial algorithm of +3–5% revenue, +4–6% adj. profit and +5–8% adj. EPS growth (with 2026 expected at the lower end while transformation investment continues).
• Smokeless inflection: New Categories revenue £3,621m (+7.0% c.c.) at 18.2% of group, category contribution £427m (+77.1%, margin 11.8% +470bps). Velo (modern oral) revenue +47% c.c. and Velo Plus reached #2 in US volume and value within twelve months of national rollout.
• US returned to growth in both revenue AND profit for the first time since 2022 — combustibles value share +20bps, volume share flat, helped by enhanced commercial execution and early federal/state enforcement against illicit disposable vapes.
• High and progressive cash returns: 2.0% dividend uplift to 245.04p (paid in four equal quarterly instalments of 61.26p), £1.3bn 2026 buyback; ~£6.3bn returned in 2025 and ~£34bn returned to shareholders since 2020. Trailing dividend yield ~5.9% on the FY25 declared dividend.
• ITC stake monetisation. After the March 2024 ~3.5% block (~£1.6bn proceeds) and the May 2025 ~2.5% block (~₹12,941 crore / ~$1.5bn), BAT’s ITC holding is now ~22.9% — below the 25% threshold that previously gave veto rights, freeing further potential capital recycling. BAT also signalled in December 2025 it is exploring a sell-down of its ITC Hotels stake (subject to RBI approval).
• Innovation pipeline now in market: glo Hilo with TurboStart heating launched Japan (Sept 2025), Poland (Oct), Italy (Nov); Vuse Ultra premium pod platform live in Canada, Germany, France; Velo Shift launched in 2025.

Bear Case

• Combustibles volumes structurally declining; total combustibles volume −5% in FY24 and remained negative in FY25 (high-single-digit declines in some markets). Group revenue still −1.0% reported in FY25.
• Vuse under sustained pressure: full-year Vuse revenue declined ~high-single-digit at constant rates and volume −12.6% as illegal disposable vapes (predominantly Chinese-origin) continue to siphon US, UK and European demand. H1 2025 Vuse revenue alone was −13–15%.
• Free cash flow weak: operating cash flow £6,342m (−37.4% YoY) and free cash pre-dividend £4,048m (−48.8%) reflect working-capital build, capex on glo Hilo / Vuse Ultra production, and a one-off Canadian CCAA settlement (the FY24 reported figure benefitted from a non-recurring tailwind that didn’t repeat).
• 2–3% FX headwind to adjusted diluted EPS guided for both H1 and FY 2026 (Chair’s AGM 15 April 2026 address); 2026 is a "lower-end" delivery year for the financial algorithm.
• Regulation tightening: UK Tobacco and Vapes Bill received final passage 21 April 2026 (generational sales ban from 1 Jan 2027 for anyone born 1 Jan 2009 or later, plus expanded vape flavour and packaging powers); UK disposable vape ban already in force since June 2025; UK vaping liquid duty from October 2026; EU TPD evaluation underway. ZYN (Philip Morris) holds >50% US pouch share — competition for Velo intense.
• Net debt £35.07bn (incl. leases) and adj. net debt / EBITDA 2.48x — near the top of management’s 2.0–2.5x corridor; capital structure leaves limited headroom for deal flexibility absent further ITC monetisation.
• US litigation tail. Engle progeny cases against Reynolds Tobacco continue (legacy Florida class action progeny) and the perpetual MSA payments framework remains a permanent annual cash outflow on US operations.

3. What Does British American Tobacco Actually Do?

BAT manufactures and distributes nicotine products in roughly 180 countries. The portfolio splits into two strategic buckets — combustibles (traditional cigarettes and roll-your-own / fine-cut tobacco) and "New Categories" / Smokeless (vapour, heated tobacco, modern oral pouches, traditional oral and the Zonnic NRT line in Canada and parts of Europe).

FY2025 revenue mix — by product category (group total £25.61bn):

• Combustibles — Dunhill, Lucky Strike, Pall Mall, Camel (US), Newport (US menthol), Kent, Rothmans, Vogue, Viceroy. ~81.8% of revenue (~£20.95bn). Includes "Strategic Combustible Brands" which BAT prioritises behind premium pricing and innovation (e.g., Lucky Strike Click variants).
• Vapour (Vuse) — pod system Vuse Alto in the US (Marketing Granted Order issued by FDA on tobacco-flavour Vuse Solo / Alto products; menthol MDOs under appeal), Vuse Go (closed disposable for international markets), and the new premium Vuse Ultra platform in Canada/Germany/France. Vuse revenue declined high single digits at constant FX in 2025 with volume −12.6%.
• Heated Products (glo) — glo Hyper, glo Hilo (premium with TurboStart five-second heat-up, AMOLED EasyView screen and myglo app). H2 2025 launches in Japan, Poland, Italy. neo and veo consumable sticks, plus the new "virto" sticks for Hilo.
• Modern Oral (Velo / Zonnic) — Velo nicotine pouches and the new Velo Plus US line. FY25 Modern Oral revenue +47% at constant FX. Velo Plus reached #2 in US volume and value share within 12 months. ZYN (Philip Morris) remains brand leader with >50% US share.
• Traditional Oral & Other Smokeless — US smokeless tobacco (Grizzly, Camel Snus — legacy pre-Reynolds heritage) and Zonnic NRT (nicotine replacement therapy) in Canada.

Smokeless / New Categories combined: £3,621m revenue (~14.1% of group), plus traditional oral; together "smokeless" totals 18.2% of group revenue (+70bps YoY). Long-term target: 50% of revenue from non-combustibles by 2035.

FY2025 revenue mix — by region (constant-currency revenue moves): the US (Americas) is the largest region by revenue and profit; AME (Africa, Middle East, Europe) is the broad international engine; APMEA (Asia-Pacific, Middle East, Africa) covers Asia plus parts of the Middle East and Africa, and was held back in 2025 by fiscal/regulatory headwinds in Bangladesh and Australia. AME revenue grew +3.5% constant currency in 2025, led by combustibles price/mix +6.8% and Modern Oral +16.5%. The US revenue grew +2.1% constant currency.

4. The Business Model

BAT’s economic engine is high-margin combustible cigarettes generating extremely strong cash flow that is being progressively redeployed into higher-growth (but lower-margin and capital-hungry) smokeless categories, while sustaining the group’s dividend and buyback. FY2025 adjusted operating margin held flat at 44.0% — a hallmark of the industry’s pricing power despite volume pressure.

How it makes money:

1. Combustible price/mix. Volumes decline ~3–6% per year industry-wide; BAT offsets via annual price increases (typically inflation+) and trading consumers up the premium ladder (Strategic Combustible Brands). FY25 US combustibles delivered the bulk of profit growth via price/mix and excise pass-through.
2. New Category contribution. Vuse, glo and Velo are now self-funding at the contribution level: New Categories category contribution £427m in FY25 (+77.1%) at an 11.8% margin (+470bps YoY). Modern Oral is the best-margin and fastest-growing line.
3. ITC dividend stream. BAT’s remaining ~22.9% stake in ITC Limited (India) generates a recurring dividend stream (the Indian FMCG/cigarette major’s payout). The stake was ~29% before the March 2024 block (3.5% sold ~£1.6bn) and the May 2025 block (2.5% sold ~$1.5bn). BAT also still owns ~30.6% of ITC Hotels (the demerger entity) and signalled in December 2025 it intends to sell that down, subject to RBI approval.
4. Working capital and capex discipline. Capex guided ~£750m in 2026; cash conversion target >95%; net finance costs ~£1.8bn.

Moat: regulated brand portfolio with high barriers to entry (advertising bans freeze incumbent share), distribution scale across ~180 markets, and a global manufacturing footprint enabling premium device industrialisation (Italian-made Hilo lines, US-manufactured Velo Plus). Patents on Vuse pod design, glo heating element and Hilo TurboStart support innovation defensibility.

Subsidy / regulatory-credit dependency: nil. Tobacco companies do not receive government subsidies or tax credits; instead they pay extensive excise duties (most countries) and, in the US, contribute to the Tobacco Master Settlement Agreement (MSA) — a perpetual-payment regime estimated at ~$9bn industry-wide annually from 2018 onwards. Reynolds American (BAT US) and BAT separately face Engle progeny case provisions in Florida. These outflows are liabilities, not subsidies, and constitute a permanent drag rather than an upside lever.

5. Financial Health

BAT reports half-yearly (H1 trading update + Interim, FY pre-close + Preliminary). It does not publish quarterly P&L. Five-year reported and adjusted figures (£m unless stated, source: BAT FY24 / FY25 preliminary results announcements):

Metric	FY21	FY22	FY23	FY24	FY25
Revenue (reported)	25,684	27,655	27,283	25,867	25,610
Profit / (loss) from operations (reported)	10,233	10,529	(15,751)	2,735	9,997
Adj. profit from operations (c.c. growth)	+5.2%	+3.3%	+1.6%	+1.2%	+0.4%
Adjusted operating margin	44.7%	45.7%	45.4%	44.0%	44.0%
Adjusted diluted EPS (p)	330.0	359.4	372.8	349.6	352.1
Reported diluted EPS (p)	299.4	289.8	(669.7)	135.7	349.1
Operating cash flow	9,696	9,479	10,030	10,124	6,342
Free cash flow (pre-dividend)	8,313	7,853	8,394	7,901	4,048
Net debt (incl. leases)	40,116	38,839	33,259	36,962	35,070
Adj. net debt / EBITDA	2.92x	2.78x	2.69x	2.43x	2.48x
Total dividend (p)	217.8	230.9	235.5	240.24	245.04
Smokeless revenue (£bn)	2.05	2.89	3.35	3.43	3.62
Smokeless % of group	~8%	~10.5%	~12.3%	~17.5%	18.2%
Shares outstanding (year-end, m)	~2,290	~2,232	~2,225	~2,200	~2,175

Note on FY23: the £15.75bn reported operating loss reflected a £27.6bn non-cash impairment on Reynolds American combustible brand intangibles (Newport, Camel, Pall Mall — carrying values rebased to 30-year useful lives, reflecting accelerated assumed combustible decline in the US). Adjusted operating profit was unaffected. Note on FY25 cash flow: the year-on-year drop reflects working-capital normalisation and the absence of FY24’s favourable items, plus higher inventory build for Hilo / Velo Plus / Vuse Ultra. BAT publishes only half-yearly P&L, so the conditional Revenue + Gross Margin SVG is not appropriate for this stock.

6. Valuation & Market Data

Metric	Value	Notes / source date
Share price	~4,143p	Close 23 April 2026 (24 Apr last trading day before Sat 25 Apr; intra-week range ~4,100–4,210p)
Market capitalisation	~£90bn	~2,171m voting shares post-buyback
Enterprise value	~£125–127bn	Market cap + net debt £35.07bn (incl. leases), less ITC stake market value & cash
Trailing P/E (adjusted EPS)	~11.8x	Adj. diluted EPS 352.1p / 4,143p
Trailing P/E (reported EPS)	~11.9x	Reported diluted EPS 349.1p
P/S (FY25 revenue)	~3.5x	£90bn / £25.6bn
EV / EBITDA (TTM)	~8.8x	vs 10-yr median ~10.0x
P / FCF	~22.2x	FY25 FCF £4.05bn (depressed by working-capital build); ~11x on FY24 FCF
FY25 dividend	245.04p	+2.0%; paid in 4x 61.26p quarterly instalments (May / Aug / Nov / Feb 2027)
Trailing dividend yield	~5.9%	One of the highest in the FTSE 100
52-week high	~4,876.92p	Reached early 2026 around results day
52-week low	~2,916p	Mid-2025
Beta (5-yr)	~0.6	Defensive, low correlation to FTSE 100
Net debt / leverage	£35.07bn / 2.48x adj. EBITDA	Target corridor 2.0–2.5x by year-end 2026
2026 share buyback	£1.3bn	Merrill Lynch International executing 23 Apr – 29 Jun 2026 tranche; weekly RNS reporting under updated UK Listing Rule 9.6.6
Shares in issue with voting rights	2,171,268,613	Per recent RNS; 132.7m treasury shares held aside
Disclosed short interest (US ADR proxy)	~187,383 BTAFF shares (13 Mar 2026)	+77.1% MoM; LSE BATS short positions are not individually disclosed below 0.5% on the FCA register

7. What Are They Building / What’s Coming?

• glo Hilo rollout. Premium heated-tobacco device with TurboStart 5-second heating, AMOLED EasyView display, myglo app and exclusive virto sticks. Live: Japan (Sept 2025), Serbia, Poland (Oct 2025), Italy (Nov 2025; 100% Italian-made with up to 16 dedicated production lines). Further markets in 2026.
• Vuse Ultra. Premium pod system with ClearView display, Bluetooth pairing to MyVuse app, adjustable cloud/taste preferences. Currently in Canada, Germany, France — encouraging early performance per management.
• Velo Plus US scale-up. Triple-digit revenue growth in 2025; #2 brand in US volume and value within 12 months. ZYN (Philip Morris) remains brand #1 with >50% share.
• Velo Shift. Modern Oral innovation rolled out in 2025.
• Zonnic NRT. Nicotine replacement therapy product launched in Canada; supporting Modern Oral revenue growth +47% c.c. in 2025.
• FDA Marketing Granted Orders. Vuse Solo (Original) and tobacco-flavour Vuse Alto have MGOs. Six flavoured Vuse Alto products (3 menthol + 3 mixed berry) face MDOs — Reynolds Vapor secured a Fifth Circuit administrative stay on the menthol Alto MDO pending judicial review. New PMTAs filed for Hilo / Vuse Ultra US variants in due course.
• "Building a Smokeless World" target. 50m smokeless consumers by 2030 (FY25: 34.1m, +4.7m YoY; +>15% YoY consumer growth); 50% of revenue from non-combustibles by 2035.
• Capital framework. 2026 = +3–5% revenue, +4–6% adj. PFO, +5–8% adj. EPS (lower end of ranges). Translational FX headwind 2–3% on adj. EPS. £1.3bn buyback. Long-term >£50bn cumulative free cash flow target (2024–2030). Leverage to land within 2.0–2.5x by year-end 2026.
• ITC monetisation. Further ITC Hotels stake sale being prepared (subject to RBI approval); ITC Limited holding now ~22.9% (below the 25% veto threshold).
• Productivity programme — "Fit2Win". Multi-year cost programme reinvested into smokeless / digital / commercial execution.

8. Competitive Landscape

BAT competes against four other major listed multinationals plus the Chinese state monopoly (CNTC, not investible). Excluding China, the "Big Four" (PMI, BAT, JTI, Altria, Imperial Brands) hold ~67% of global cigarette volume per Euromonitor 2024.

Global cigarette / tobacco market share (2024 Euromonitor, ex-China):

Competitor	Approx global cigarette share (ex-China, 2024)	Notes
Philip Morris International (NYSE: PM)	~28%	Marlboro (ex-US), IQOS (heated), ZYN (modern oral — via Swedish Match acquisition); leader in 38 countries
British American Tobacco (LSE: BATS)	~12%	Dunhill, Lucky Strike, Pall Mall, Camel/Newport (US via Reynolds), Vuse, glo, Velo; leader in 24 countries
Japan Tobacco International (TYO: 2914)	~10%	Winston, Camel (ex-US), Mevius, Logic vapour, Ploom; #1 in 8 countries
Imperial Brands (LSE: IMB)	~9%	JPS, West, Davidoff, Winston (US), Gauloises, blu vape, Zone modern oral; #1 in 6 countries
Altria Group (NYSE: MO)	~8% (US-only; ~50% of US cigarette volume)	Marlboro (US), Black & Mild, on! pouches, NJOY vapour
CNTC (China National Tobacco Corp.)	~44% global volume incl. China; not investible	State monopoly — ~98% domestic Chinese share

Smokeless category dynamics:

• Vapour — closed-pod regulated US market: Vuse remains #1 by value share (with Marketing Granted Orders for Vuse Solo and tobacco-flavour Vuse Alto), competing with NJOY (Altria), JUUL and a large illicit Chinese-made disposable channel that BAT estimates exceeds the regulated market in unit volume. UK / EU disposables banned (UK from June 2025) reshaping competitor dynamics.
• Heated tobacco — PMI’s IQOS is the runaway global #1 (Marlboro-branded heatsticks). BAT’s glo is #2 globally; glo Hilo is the premium counter-attack. JTI’s Ploom is a distant #3.
• Modern oral pouches — PMI’s ZYN (acquired via Swedish Match) holds >50% US share; BAT’s Velo / Velo Plus is now #2 in volume and value share. Altria’s on! and Imperial’s Zone are smaller. The category is the fastest-growing nicotine segment globally.

9. Leadership and Ownership

Executive team: Tadeu Marroco (Chief Executive since May 2023; ~30 years at BAT including FD; Brazilian; previously regional director and group strategy & growth director); Javed Iqbal (Interim Chief Financial Officer); Dragos Constantinescu (incoming permanent CFO and Executive Director from 1 September 2026; currently CEO Asahi Europe & International; rejoins after 16 years previously at BAT including a stint as Group Operations Director); David Waterfield (President & CEO, Reynolds American — co-presented at CAGNY 2026); Kingsley Wheaton (Chief Marketing Officer); Zafar Khan (Director, Operations).

Board: Luc Jobin (Chair — tenure extended by 2 years per February 2026 board update; former CEO of Canadian National Railway); Holly Keller Koeppel stepped down at the conclusion of the 15 April 2026 AGM after 9 years (had previously served as Senior Independent Director and Audit Committee Chair). Senior Independent Director appointment communicated in February 2026 board update.

Top institutional shareholders (per most recent disclosures):

Holder	Approx stake	Notes
Capital Research & Management (Capital Group)	~14%	Largest single institutional holder; combined World / International / Capital International funds
BlackRock Investment Management (UK)	~7–10%	Disclosed Significant Holding
The Vanguard Group	~5–9%
Capital International Investors	~2.9% (~64m shares)
Fidelity Management & Research	<5%
Free float / institutional aggregate	~67%	Top 15 shareholders ~50%; no single majority owner

Recent insider / PDMR transactions (last ~6 months, source: BATS RNS):

Date	PDMR / Holder	Action	Shares / price
~mid Apr 2026	Zafar Khan (Director, Operations)	Notification of transaction	18,330 ordinary 25p shares disclosed
9 Apr 2026	Dragos Constantinescu	Appointment as CFO and Executive Director from 1 Sept 2026 (RNS announcement; not a share transaction)	n/a
21 Apr 2026	Company (own shares)	Buyback — cancellation	165,639 shares @ VWAP 4,165.6818p
22 Apr 2026	Company (own shares)	Buyback — cancellation	165,340 shares @ VWAP 4,103.8172p (counterparty: Banco Santander)
20 Apr 2026	Company (own shares)	Buyback — cancellation	163,992 shares @ VWAP 4,207.5002p
Late Mar / early Apr 2026	Multiple PDMRs	Standard ESOP / matching share allocations and dividend reinvestment	Routine RNS

Activity profile: BAT’s management ownership is modest in absolute share terms but dominated by long-vested LTIP grants and Annual Share Reward / Sharesave / Partnership Share schemes. The dominant flow in recent RNS is the £1.3bn 2026 buyback (now reported on a weekly basis to the LSE following the UK Listing Rule 9.6.6 update in early 2026, replacing the previous daily disclosure cadence). New CFO Dragos Constantinescu’s remuneration package and any initial share allocations will be disclosed when he takes office on 1 September 2026.

10. Risks and Challenges

• Regulatory — UK. Tobacco and Vapes Bill received final Parliamentary passage 21 April 2026; royal assent expected shortly. Generational sales ban (no sales to anyone born on/after 1 January 2009) takes effect 1 January 2027, gradually shrinking the UK addressable cigarette market. The bill also expands powers over vape flavours, packaging and where vaping is permitted (banned in playgrounds, outside schools, in hospitals, in cars carrying children). UK disposable vape ban already in force from June 2025; vape liquid duty starts October 2026.
• Regulatory — EU. European Commission’s evaluation of the Tobacco Products Directive (TPD) framework published in April 2026 received a "negative opinion" from the Commission’s own Regulatory Scrutiny Board. BAT publicly criticised the evaluation on 2 April 2026 for sidelining evidence on smokeless reduced-risk products. Outcome will shape EU TPD-3 in 2026–27.
• Regulatory — US. Trump administration formally withdrew the proposed federal menthol cigarette ban in January 2025 (a positive for BAT’s Newport business). However, six flavoured Vuse Alto products (3 menthol + 3 mixed berry) face FDA Marketing Denial Orders — Reynolds Vapor secured a Fifth Circuit administrative stay on the menthol Alto MDO. Continued FDA scrutiny of vape PMTAs and disposable enforcement remains material.
• Illicit disposable vapes. Estimated to exceed the regulated US vape market in unit volume; major drag on Vuse revenue (FY25 Vuse revenue −high single-digit, volume −12.6%). Remediation depends on federal/state enforcement — CEO Marroco has explicitly framed 2026 return-to-growth as enforcement-dependent.
• US litigation tail. Reynolds American (BAT US subsidiary) is exposed to Engle progeny cases — thousands of Florida individual smoker cases descending from the 2006 Engle Florida class action. Routine adverse verdicts continue (e.g., Reynolds, Lorillard, PM USA settled large tranches via Engle progeny settlements; new individual cases proceed). MSA payments are a perpetual annual charge to US tobacco majors.
• Combustible volume decline. Industry combustible volumes fall ~3–6% per year structurally; BAT relies on price/mix to offset. Over time, geographies pivot toward smokeless and the offset diminishes.
• FX translation. ~2–3% adjusted diluted EPS headwind guided for FY2026 (sterling vs USD, INR, AUD, ZAR, BRL).
• Leverage. Adj. net debt / EBITDA at 2.48x — near top of the 2.0–2.5x corridor; limits acquisition / capital-allocation optionality unless ITC monetisation continues.
• Geopolitical. BAT flagged at the AGM that it is monitoring the Middle East conflict for AME / APMEA exposure. Bangladesh and Australia tax/regulatory headwinds were specifically called out as APMEA drags.
• Competitive. PMI’s ZYN dominates US modern oral; PMI’s IQOS leads global heated tobacco. BAT must keep narrowing the gap with Velo Plus / glo Hilo without compromising margin.
• ESG / health. Tobacco causes ~8 million deaths globally per year per WHO. BAT’s "smokeless world" positioning is contested by public-health bodies (e.g., Smoke Free Partnership) which view all nicotine products including pouches as harmful. Many ESG mandates exclude tobacco; BAT is excluded from a number of FTSE4Good-style indexes despite progress disclosures. Tobacco is a controversial sector and investors should weigh that against the cash-return profile.

11. Recent Developments

• 24–25 April 2026 (last 48h). No new BAT-issued RNS in the immediate 48-hour window beyond the rolling weekly buyback execution by Merrill Lynch International (the new tranche commenced 23 April 2026). The 21 April final Parliamentary passage of the UK Tobacco and Vapes Bill was the dominant industry-level news affecting BATS; share price held in a 4,100–4,210p range over 22–23 April. Saturday 25 April: market closed.
• 23 April 2026. New share buyback agreement with Merrill Lynch International commenced (running 23 April – 29 June 2026 tranche under the £1.3bn 2026 programme); weekly RNS reporting under the updated UK Listing Rule 9.6.6.
• 22 April 2026. BAT repurchased 165,340 ordinary shares from Banco Santander @ VWAP 4,103.82p (intraday low 4,090; high 4,160).
• 21 April 2026. UK Parliament gave the Tobacco and Vapes Bill its final passage (Lords consideration of Commons amendments). Generational ban from 1 January 2027 confirmed. Same day, BAT bought back 165,639 shares @ VWAP 4,165.68p.
• 15 April 2026 — AGM 2026. Chair Luc Jobin’s address: re-iterated +3–5% / +4–6% / +5–8% medium-term financial algorithm with 2026 at the lower end; flagged 2–3% FX headwind on adjusted diluted EPS for both H1 and FY 2026; smokeless consumers +>15% YoY; ~£6.3bn returned to shareholders in 2025 and ~£34bn since 2020. Holly Keller Koeppel stepped down at end of AGM.
• 9 April 2026. RNS — Dragos Constantinescu appointed Chief Financial Officer and Executive Director, effective 1 September 2026, joining from Asahi Europe & International (where he is currently CEO).
• 2 April 2026. Press release: BAT publicly criticised the European Commission’s tobacco-control framework evaluation, arguing it sidelined evidence on smokeless reduced-risk categories and risks the EU’s 2040 smoke-free goal.
• March 2026. Buyback execution under earlier tranche; routine PDMR ESOP / matching share allocations.
• February 2026. Chair’s tenure extended by 2 years (board update); Senior Independent Director appointment; CAGNY 2026 conference appearance by Marroco / Waterfield reaffirming FY26 guidance.
• 12 February 2026 — FY2025 Preliminary Results. Revenue £25,610m (−1.0% reported / +2.1% c.c.); adj. PFO £11,572m (+0.4% c.c.); adj. operating margin 44.0%; adj. diluted EPS 352.1p (+0.7% c.c.); reported diluted EPS 349.1p (+157% reported, recovery from FY23 impairment base); FY25 dividend 245.04p (+2.0%); 2026 buyback £1.3bn announced; smokeless 18.2% of revenue (+70bps); New Categories revenue £3,621m (+7.0% c.c.) with category contribution £427m (+77.1%) at 11.8% margin (+470bps); adj. net debt / EBITDA 2.48x; FY25 OCF £6,342m (−37.4%) and FCF pre-dividend £4,048m (−48.8%) reflecting working-capital build.
• December 2025 — Full-Year Pre-Close Trading Update. Smokeless growth re-accelerated to double-digit in H2; Vuse FY revenue down high single-digit; Velo Plus up triple-digit in US; glo Hilo H2 launches in Japan / Poland / Italy. Bloomberg also reported BAT exploring a sell-down of its ITC Hotels stake (subject to RBI approval).
• July 2025 — Half-Year Report. H1 revenue +1.0% c.c.; New Categories +1.8% c.c. (subdued before H2 acceleration); Velo volume share in top markets reached 29.7%; Vuse revenue −15% in H1 reflecting illicit disposable headwinds; CEO Marroco signalled 2026 as the return to algorithm year.
• June 2025. glo Hilo launched in Japan with TurboStart 5-second heat-up technology and AMOLED display; UK disposable vape ban came into force; First Half pre-close update.
• 28 May 2025 — Second ITC block sale. BAT sold 313m ordinary ITC shares (~2.5% stake) by accelerated bookbuild; ~₹12,941 crore (~$1.5bn) net proceeds; BAT’s ITC stake fell below the 25% veto threshold to ~22.93% (some reporting cites ~20.3% pro forma for combined disposals). Proceeds redeployed toward 2025 buyback & deleverage to within 2.0–2.5x by year-end 2026.

12. Key Dates Coming Up

• Late April / early May 2026 — weekly buyback RNS (Merrill Lynch International tranche running 23 April – 29 June 2026).
• ~7 May 2026 — first 61.26p quarterly dividend payment (one-quarter of the 245.04p FY25 dividend); subsequent payments in August 2026, November 2026, and February 2027.
• ~July 2026 — First Half Pre-Close Trading Update.
• ~End July 2026 — H1 2026 Half-Year Report (Interim Results) — first quarterly dividend ex-date 9 July 2026 historically.
• 1 September 2026 — new CFO Dragos Constantinescu starts.
• October 2026 — UK vaping liquid duty takes effect.
• November 2026 — Q3 quarterly dividend payment.
• December 2026 — Full Year Pre-Close Trading Update.
• End-2026 deleverage milestone — management target adj. net debt / EBITDA within 2.0–2.5x corridor.
• 1 January 2027 — UK generational tobacco sales ban begins (no legal sales to anyone born on/after 1 January 2009).
• ~February 2027 — FY2026 Preliminary Results (estimated).
• 2030 strategic milestone — 50m smokeless consumers target (FY25 base 34.1m).
• 2035 — 50% of revenue from non-combustibles target.
• 2024–2030 cumulative — >£50bn free cash flow target.

Related

For live charts and watchlists, see our live charts. UK macro, BoE rate decisions and FX moves all feed into BAT’s reported numbers — track them on the economic calendar. Discuss this report in the community forum, and browse more company research on the blog.

Disclaimer: Research only. This article is for information and discussion purposes. It is not investment advice, not a recommendation to buy or sell any security, and does not take your personal circumstances into account. Tobacco is a controversial sector with documented public-health harms; many investors and institutional mandates exclude it on ethical or ESG grounds. All financial figures come from British American Tobacco p.l.c. results announcements, RNS, AGM materials and investor disclosures; market data is as of the dates stated. Always do your own research and consult a qualified adviser before making investment decisions.